Pancreatic Cancer Research

ResearcherFujita Health UniversityActive in the last 2 years

Takashi Kobayashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9202-7643; OpenAlex author ID A5036438602. Sources: OpenAlex.

Their work

Papers
28 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
62
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: 1 paper · 2015: 2 papers · 2016: 2 papers · 2017: 2 papers · 2018: 4 papers · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 5 papers · 2024: 4 papers · 2025: none · 2026: 1 paper

Papers 28

  1. Deep Learning Detection of Direct and Indirect Imaging Findings Associated with Pancreatic Cancer at Contrast-enhanced and Noncontrast CT. Co-author DOI 10.1148/radiol.253122↗
  2. Temporal progression of pancreatic cancer computed tomography findings until diagnosis: A large-scale multicenter study. Co-author DOI 10.1002/ueg2.12557↗
  3. Impact of intratumoral microbiome on tumor immunity and prognosis in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-023-02069-5↗
  4. Association of pancreatic atrophy patterns with intraductal extension of early pancreatic ductal adenocarcinoma: a multicenter retrospective study. Co-author DOI 10.1007/s00535-024-02149-0↗
  5. Treatment and Prognosis for Pancreatic Duct Disruption Associated With Pancreatic Cancer: A Case Series of 15 Patients. Co-author DOI 10.7759/cureus.67482↗
  6. Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-022-01939-8↗
  7. A comprehensive analysis of tumor-stromal collagen in relation to pathological, molecular, and immune characteristics and patient survival in pancreatic ductal… Co-author DOI 10.1007/s00535-023-02020-8↗
  8. A case of pancreatic ductal adenocarcinoma concomitant with IgG4-related disease in the pancreas and the stomach. First author DOI 10.1007/s12328-023-01814-w↗
  9. Benefits of pancreatic parenchymal endoscopic ultrasonography in predicting microscopic precancerous lesions of pancreatic cancer. Co-author DOI 10.1038/s41598-023-38920-1↗
  10. Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma: A Retrospective Anal… Co-author DOI 10.1245/s10434-023-13569-2↗
  11. Comprehensive Analysis of Molecular Biologic Characteristics of Pancreatic Ductal Adenocarcinoma Concomitant with Intraductal Papillary Mucinous Neoplasm. Co-author DOI 10.1245/s10434-022-11704-z↗
  12. Possibility of detecting intraductal papillary mucinous neoplasms using metabolite biomarkers for pancreatic cancer. Co-author DOI 10.2217/bmm-2019-0587↗
  13. Prospective Study Using Plasma Apolipoprotein A2-Isoforms to Screen for High-Risk Status of Pancreatic Cancer. First author DOI 10.3390/cancers12092625↗
  14. Trends in biomarker discoveries for the early detection and risk stratification of pancreatic cancer using omics studies Co-author DOI 10.1080/14737159.2019.1643718↗
  15. Pancreatic inflammation and atrophy are not associated with pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. Co-author DOI 10.1016/j.pan.2017.12.007↗
  16. Multifocal cysts and incidence of pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. Co-author DOI 10.1016/j.pan.2018.04.005↗
  17. Increased Levels of Branched-Chain Amino Acid Associated With Increased Risk of Pancreatic Cancer in a Prospective Case-Control Study of a Large Cohort. Co-author DOI 10.1053/j.gastro.2018.07.033↗
  18. Metabolome analysis for pancreatic cancer risk in nested case-control study: Japan Public Health Center-based prospective Study. First author DOI 10.1111/cas.13573↗
  19. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics. First author DOI 10.1016/j.cca.2017.02.011↗
  20. Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm. Co-author DOI 10.1097/mpa.0000000000000761↗
  21. Pancreatic cancer screening using a multiplatform human serum metabolomics system. Co-author DOI 10.2217/bmm-2016-0020↗
  22. [Long-Term Survival after Reoperation for Lung Metastasis of Resected Pancreatic Adenocarcinoma - A Case Report]. Co-author PMID 28133268↗
  23. Effectiveness of endoscopic self-expandable metal stent placement for afferent loop obstruction caused by pancreatic cancer recurrence after pancreaticoduodene… Co-author DOI 10.1007/s12328-015-0556-0↗
  24. [A Case of Radical Resection for Locally Advanced Pancreatic Cancer with Positive Peritoneal Cytology Treated with Chemoradiotherapy]. Co-author PMID 26805372↗
  25. Metabolomics evaluation of serum markers for cachexia and their intra-day variation in patients with advanced pancreatic cancer. First author DOI 10.1371/journal.pone.0113259↗
  26. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Co-author DOI 10.1158/1055-9965.epi-12-1033↗
  27. Serum metabolomic analysis of pancreatic cancer--response. Co-author DOI 10.1158/1055-9965.epi-13-0740↗
  28. Development of pancreatic ductal adenocarcinoma associated with intraductal papillary mucinous neoplasia. Co-author DOI 10.5402/2011/940378↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Atsuhiro Masuda · 15 shared papers, 2017–2026 · strength 1.89
  2. Arata Sakai · 15 shared papers, 2015–2026 · strength 1.88
  3. Yuzo Kodama · 12 shared papers, 2020–2024 · strength 1.64
  4. Hirochika Toyama · 13 shared papers, 2017–2024 · strength 1.61
  5. Masanori Gonda · 10 shared papers, 2022–2026 · strength 1.46
  6. Keitaro Sofue · 11 shared papers, 2017–2026 · strength 1.31
  7. Takumi Fukumoto · 11 shared papers, 2017–2024 · strength 1.29
  8. Masahiro Tsujimae · 8 shared papers, 2022–2024 · strength 1.09
  9. Mika Miki · 7 shared papers, 2023–2026 · strength 1.05
  10. Kohei Yamakawa · 7 shared papers, 2022–2024 · strength 0.94
  11. Shohei Abe · 7 shared papers, 2022–2024 · strength 0.94
  12. Takeshi Tanaka · 7 shared papers, 2022–2024 · strength 0.93
  13. Tomoo Itoh · 7 shared papers, 2022–2024 · strength 0.93
  14. Takuya Ikegawa · 7 shared papers, 2018–2026 · strength 0.85
  15. Shigeto Ashina · 6 shared papers, 2022–2026 · strength 0.81
  16. Masaru Yoshida · 12 shared papers, 2013–2020 · strength 0.78
  17. Shigeto Masuda · 6 shared papers, 2022–2024 · strength 0.76
  18. Yoshiyuki Harada · 5 shared papers, 2023–2024 · strength 0.70
  19. Ryota Nakano · 5 shared papers, 2020–2024 · strength 0.68
  20. Takeshi Azuma · 10 shared papers, 2013–2018 · strength 0.53
  21. Yuichi Hirata · 5 shared papers, 2016–2026 · strength 0.52
  22. Mamoru Takenaka · 6 shared papers, 2015–2024 · strength 0.52
  23. Takashi Nakagawa · 6 shared papers, 2016–2018 · strength 0.38
  24. Kazufumi Honda · 3 shared papers, 2017–2020 · strength 0.34
  25. Yuki Oka · 2 shared papers, 2024 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.